



Innovative ocular and cancer therapeutics

Biotech & Money Online Showcase 2-3 Feb 2016

Salman Rahman PhD

Neovascular AMD Market & Competition

- Robust \$7bn market (x3 anti-VEGFs)
- Few novel therapies in development:
 - “me too” anti-VEGFs only offer enhanced durability
 - novel, non-VEGF therapies offer enhanced efficacy/durability
- Novel therapies will capture market share
- **Anti-ADAM15 therapy peak sales \geq \$1.5bn p.a.**


Novel Monoclonal Antibody Therapeutics

First-in-Class Therapy for AMD

Anti-ADAM15 mAb

AbIMP[®]: Antibody Platform

Selective targeting of
metzincin proteases



Multi-billion \$ markets

Ophthalmology & Oncology


Investment

- 1 granted patent (US), 8 pending applications
- £100k invested from co-founders
£200k Biomedical Catalyst Feasibility Award
- **Seeking £5.5m for pre-clinical development & first-in-man studies prioritising neovascular AMD**

Neovascular AMD: Unmet Needs


- Leading cause of blindness in developed world
- No cure; variable response to anti-VEGF therapy
- Monthly anti-VEGF injections in the eye
- 65-70% patients can still improve vision (target group)
- **ADAM15/VEGF synergism: step change in efficacy**

ADAM15 is a Validated Ocular Target



- **ADAM15 is a validated ocular target:** Co-dependent expression of ADAM15 and VEGF/VEGFR2
- **ADAM15 antibodies inhibit vascular proliferation & leakage *in vivo***
- **Potential for therapeutic synergy by combined anti-VEGF/anti-ADAM15 antagonism**
- **Improved efficacy for wet AMD patients leading to improved vision**

Targeting Sub-optimal Responders



Defined target patient group: Anti-ADAM15 monotherapy or in combination with anti-VEGFs may improve outcomes for anti-VEGF sub-optimal responders

VASGEN[®] Team



CEO

Salman

Rahman

PhD

Co-founder



COO

Yatin

Patel

PhD

Co-founder



NED

Oliver

Boucher

MBA

BD



SA

John

Greenwood

Prof.

UCL



SA

James

Bainbridge


Prof.

UCL/NIHR/Moorfields

Academic Collaboration with UCL Institute of Ophthalmology



Anti-ADAM15 mAb Development Pathway



Thank You!



Contact:

Salman Rahman PhD, CEO

E-mail: salman@vasgen.co.uk

Innovative ocular and cancer therapeutics